AMPH — Amphastar Pharmaceuticals, Inc. stock price, charts and financials
QT45Amphastar Pharmaceuticals, Inc.Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) is a Healthcare company in the Drug Manufacturers - Specialty & Generic industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | 11.99 | EPS (ttm) | 1.66 | Insider Own | 14.00% | Shs Outstand | 44.09M | Perf Week | -1.24% |
| Market Cap | 877.45M | Forward P/E | 6.63 | EPS next Y | 3.00 | Insider Trans | 0.00% | Shs Float | 32.83M | Perf Month | 1.48% |
| Enterprise Value | 1.27B | PEG | - | EPS next Q | - | Inst Own | - | Short Float | 12.71% | Perf Quarter | -12.49% |
| Income | 78.00M | P/S | 1.22 | EPS this Y | 55.43% | Inst Trans | - | Short Ratio | 6.88 | Perf Half Y | -28.72% |
| Sales | 720.00M | P/B | 1.14 | EPS next Y | 16.27% | ROA | 4.81% | Short Interest | 4.17M | Perf YTD | -25.69% |
| Book/sh | 17.53 | P/C | 2.98 | EPS next 5Y | -1.18% | ROE | 10.23% | 52W High | 31.26 -36.34% | Perf Year | -6.18% |
| Cash/sh | 6.67 | P/FCF | 6.50 | EPS past 3/5Y | 5.27% 134.54% | ROIC | 6.02% | 52W Low | 16.65 19.52% | Perf 3Y | -67.29% |
| Dividend Est. | - | EV/EBITDA | 6.61 | Sales past 3/5Y | 13.00% 15.52% | Gross Margin | 47.34% | Volatility | 3.26% 3.47% | Perf 5Y | -4.28% |
| Dividend TTM | - | EV/Sales | 1.76 | EPS Y/Y TTM | -45.75% | Oper. Margin | 16.20% | ATR (14) | 0.76 | Perf 10Y | 20.10% |
| Dividend Ex-Date | Jun 11, 2010 | Quick Ratio | 2.82 | Sales Y/Y TTM | -1.64% | Profit Margin | 11.00% | RSI (14) | 51.72 | Recom | 2.83 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.85 | EPS Q/Q | -43.24% | SMA20 | 2.00% | Beta | 0.88 | Target Price | 20.50 |
| Payout | 0.00% | Debt/Eq | 0.82 | Sales Q/Q | 0.00% | SMA50 | 1.69% | Rel Volume | 0.79 | Prev Close | 20.22 |
| Employees | 1,976 | LT Debt/Eq | 0.82 | Earnings | Aug 06 | SMA200 | -13.16% | Avg Volume | 609.56K | Price | 19.90 |
| IPO Date | Jun 25, 2014 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -40.44% -1.32% | Net Debt/EBITDA | 2.69 | Volume | 481,647 | Change | -1.58% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jun-29-26 | Downgrade | B of A Securities | Neutral → Underperform | |
| Jun-03-26 | Reiterated | Barclays | Equal Weight | $30 → $20 |
| May-14-26 | Downgrade | Wells Fargo | Overweight → Equal Weight | $19 |
| May-11-26 | Reiterated | Piper Sandler | Neutral | $32 → $21 |
| May-08-26 | Downgrade | Needham | Buy → Hold | |
| Apr-21-26 | Downgrade | Jefferies | Buy → Hold | $22 |
| Dec-08-25 | Initiated | Barclays | Equal Weight | $30 |
| Aug-12-25 | Upgrade | Needham | Hold → Buy | |
| May-12-25 | Downgrade | JP Morgan | Overweight → Neutral | |
| Mar-21-25 | Reiterated | Piper Sandler | Neutral | $66 → $32 |
Amphastar Pharmaceuticals, Inc., established in 1996 and based in Rancho Cucamonga, California, functions as a biopharmaceutical enterprise. The company is engaged in the creation, production, commercialization, and distribution of both generic and proprietary pharmaceutical products, which include injectables, inhalants, and intranasal formulations. Its market presence extends across the United States, China, and France. Amphastar's operations are divided into two primary segments: Finished Pharmaceutical Products and Active Pharmaceutical Ingredients (API). The company's extensive product portfolio encompasses a variety of crucial medications. These feature Primatene Mist, an over-the-counter epinephrine inhaler for the temporary alleviation of mild asthma symptoms; Enoxaparin, a low molecular weight heparin utilized for the prevention and treatment of deep vein thrombosis; and Naloxone, an essential treatment for opioid overdose. Other significant offerings include emergency Glucagon injection kits; Cortrosyn, a diagnostic agent for adrenocortical insufficiency; and Amphadase, a bovine-sourced hyaluronidase injection that aids in the absorption and dispersion of other administered drugs. Amphastar additionally supplies Epinephrine injections for severe allergic reactions; various lidocaine products (such as a jelly for urological procedures and a topical solution for other applications); Phytonadione injection (Vitamin K1) for newborns; and specialized emergency syringe products for hospital use. Furthermore, the company provides Morphine injections for patient-controlled analgesia and Lorazepam injections for surgical and medical procedures. More advanced therapeutics consist of Neostigmine methylsulfate injection to manage myasthenia gravis and reverse muscle relaxant effects, and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Beyond its finished pharmaceutical goods, Amphastar also acts as a distributor for recombinant human insulin API and porcine insulin API. The company caters to a broad spectrum of healthcare providers, including hospitals, various care facilities, clinics, and physicians' offices.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 720 | 720 | 732 | 644 | 499 | 438 | 350 | 322 | 295 | |
| Cost of Goods Sold Incl. D&A | 379 | 364 | 358 | 293 | 250 | 238 | 207 | 190 | 188 | |
| Gross Profit | 341 | 356 | 374 | 351 | 249 | 200 | 143 | 132 | 107 | |
| Selling, General and Administrative Excl. Other | 132 | 130 | 95 | 80 | 67 | 69 | 65 | 63 | 58 | |
| Research and Development | 92 | 86 | 74 | 74 | 75 | 61 | 67 | 69 | 58 | |
| Other Operating Expense | 0 | 0 | -1 | 0 | -1 | 0 | 0 | 0 | 0 | |
| Operating Income | 117 | 140 | 205 | 197 | 107 | 70 | 11 | 0 | -9 | |
| Interest Expense | 26 | 25 | 30 | 27 | 2 | 1 | 0 | 0 | 0 | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 11 | 9 | 14 | 0 | 9 | 15 | -6 | 60 | -1 | |
| Net Income Before Taxes | 103 | 124 | 189 | 169 | 115 | 84 | 5 | 60 | -10 | |
| Income Taxes | 23 | 26 | 30 | 32 | 23 | 21 | 4 | 14 | -3 | |
| Consolidated Net Income | 78 | 98 | 160 | 138 | 91 | 62 | 1 | 49 | -6 | |
| Net Income From Continuing Operations | 78 | 98 | 160 | 138 | 91 | 63 | 1 | 47 | -7 | |
| Net Income | 78 | 98 | 160 | 138 | 91 | 62 | 1 | 49 | -6 | |
| EPS (Recurring) | 1.71 | 2.10 | 3.29 | 2.85 | 1.88 | 1.30 | 0.03 | 1.04 | -0.12 | |
| EPS (Basic, Before Extraordinaries) | 1.71 | 2.10 | 3.29 | 2.85 | 1.88 | 1.30 | 0.03 | 1.04 | -0.12 | |
| EPS (Diluted) | 1.66 | 2.03 | 3.06 | 2.60 | 1.74 | 1.25 | 0.03 | 0.98 | -0.12 | |
| EBITDA | 192 | 212 | 277 | 240 | 146 | 112 | 30 | 81 | 7 | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 11.99 | 13.19 | 12.13 | 23.79 | 16.10 | 18.63 | 703.15 | 19.68 | — | |
| Price To Sales Ratio | 1.24 | 1.75 | 2.43 | 4.61 | 2.75 | 2.55 | 2.70 | 2.82 | 3.10 | |
| Gross Margin | 47.36 | 49.44 | 51.09 | 54.50 | 49.90 | 45.66 | 40.86 | 40.99 | 36.27 | |
| Operating Margin | 16.25 | 19.44 | 28.01 | 30.59 | 21.44 | 15.98 | 3.14 | 0.00 | -3.05 | |
| Net Margin | 10.83 | 13.61 | 21.86 | 21.43 | 18.24 | 14.16 | 0.29 | 15.22 | -2.03 | |
| Shares Outstanding | 45 | 47 | 48 | 48 | 49 | 48 | 47 | 47 | 46 | |
| Market Capitalization | 895 | 1,259 | 1,782 | 2,969 | 1,373 | 1,118 | 945 | 907 | 915 | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Zhou Rong | SENIOR EVP, PRODUCTION CENTER | Dec 17 '25 | Option Exercise | 11.33 | 9,787 | 110,887 | 147,830 | Dec 18 |
| Zhou Rong | SENIOR EVP, PRODUCTION CENTER | Dec 17 '25 | Sale | 26.20 | 9,787 | 256,379 | 138,043 | Dec 18 |
| Petersen Floyd F. | Director | Dec 12 '25 | Sale | 25.92 | 2,426 | 62,888 | 71,368 | Dec 15 |
| Petersen Floyd F. | Director | Dec 11 '25 | Sale | 25.69 | 1,737 | 44,620 | 73,794 | Dec 15 |
| PRINS RICHARD K | Director | Nov 25 '25 | Sale | 27.10 | 4,179 | 113,253 | 35,183 | Nov 25 |
| PRINS RICHARD K | Director | Nov 25 '25 | Option Exercise | 16.69 | 4,179 | 69,748 | 39,362 | Nov 25 |
| Petersen Floyd F. | Director | Nov 13 '25 | Sale | 26.49 | 16,679 | 441,837 | 75,531 | Nov 17 |
| Petersen Floyd F. | Director | Nov 13 '25 | Option Exercise | 16.69 | 16,679 | 278,373 | 92,210 | Nov 17 |
| Petersen Floyd F. | Director | Nov 03 '25 | Sale | 25.27 | 500 | 12,633 | 75,531 | Nov 05 |
| Petersen Floyd F. | Director | Oct 01 '25 | Sale | 27.20 | 500 | 13,602 | 76,031 | Oct 02 |
| Petersen Floyd F. | Director | Sep 02 '25 | Sale | 30.98 | 500 | 15,492 | 76,531 | Sep 03 |
| Petersen Floyd F. | Director | Aug 01 '25 | Sale | 20.83 | 500 | 10,416 | 77,031 | Aug 04 |
| Petersen Floyd F. | Director | Jul 02 '25 | Sale | 23.47 | 500 | 11,734 | 77,531 | Jul 03 |
| Zhang Jack Y. | CEO & CHIEF SCIENTIFIC OFFICER | Jun 13 '25 | Option Exercise | 13.03 | 200,000 | 2,606,000 | 2,847,659 | Jun 16 |
| Petersen Floyd F. | Director | Jun 02 '25 | Sale | 25.67 | 500 | 12,835 | 72,909 | Jun 04 |